MA39288A - Formulations pharmaceutiques comprenant du vilanterol - Google Patents

Formulations pharmaceutiques comprenant du vilanterol

Info

Publication number
MA39288A
MA39288A MA039288A MA39288A MA39288A MA 39288 A MA39288 A MA 39288A MA 039288 A MA039288 A MA 039288A MA 39288 A MA39288 A MA 39288A MA 39288 A MA39288 A MA 39288A
Authority
MA
Morocco
Prior art keywords
vilanterol
pharmaceutical formulations
formulation
bpco
prophylaxis
Prior art date
Application number
MA039288A
Other languages
English (en)
Inventor
Özlem Akdas
Devrim Celik
Ali Türkyilmaz
Original Assignee
Arven Ilac Sanayi Ve Ticaret As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arven Ilac Sanayi Ve Ticaret As filed Critical Arven Ilac Sanayi Ve Ticaret As
Publication of MA39288A publication Critical patent/MA39288A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention se rapporte à une formulation pharmaceutique pour inhalation comprenant vilanterol en tant qu'agent actif, un excipient et du stéarate de magnésium dans le traitement et la prophylaxie des maladies respiratoires telles que l'asthme, la broncho-pneumopathie chronique obstructive (bpco), ainsi qu'à un procédé pour produire ce formulation.
MA039288A 2014-06-16 2015-06-15 Formulations pharmaceutiques comprenant du vilanterol MA39288A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR201406982 2014-06-16

Publications (1)

Publication Number Publication Date
MA39288A true MA39288A (fr) 2015-12-23

Family

ID=52544546

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039288A MA39288A (fr) 2014-06-16 2015-06-15 Formulations pharmaceutiques comprenant du vilanterol

Country Status (2)

Country Link
EP (1) EP2957550A1 (fr)
MA (1) MA39288A (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
CA2458534C (fr) 2001-09-14 2011-11-01 Glaxo Group Limited Derives de phenethanolamine destines au traitement de maladies respiratoires
PL2400950T3 (pl) * 2009-02-26 2019-12-31 Glaxo Group Limited Preparaty farmaceutyczne zawierające 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzylo)oksy]etoksy}heksylo)amino]-1-hydroksyetylo}-2-(hydroksymetylo)fenol

Also Published As

Publication number Publication date
EP2957550A1 (fr) 2015-12-23

Similar Documents

Publication Publication Date Title
CY1123391T1 (el) (2s)-n-[(1s)-1-kyano-2-φainyλaιθyλ]-1,4-oξazeπan-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης ι
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
MX2019003397A (es) Metodos para tratar trastornos mitocondriales y metabolicos.
BR112018010650A2 (pt) pró-fármacos de um inibidor de jak composto para o tratamento da doença inflamatória gastrointestinal
MX2014013523A (es) Preparaciones de agentes terapeuticos hidrofobos, metodos de elaboracion y uso de los mismos.
BR112017010551A2 (pt) composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento.
PH12017502087A1 (en) Tiotropium inhalation solution for nebulization
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
EA201800499A1 (ru) Ингибитор тирозинкиназы для лечения амиотрофного латерального склероза, композиция, лекарственное средство, набор
MX2018006247A (es) Metodos para tratar la enfermedad de alzheimer y trastornos relacionados.
EA201891931A1 (ru) Новые ингибиторы фосфатидилинозитол-3-киназы гамма
MX2023009856A (es) Dosificacion optimizada de diaminofenotiazinas en poblaciones.
MA38646B1 (fr) Formulation a liberation modifiee pour traiter, par ex. La maladie de parkinson et la dyskinesie induite par l-dopa.
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
BR112014026439A2 (pt) comprimidos revestidos e produção dos mesmos
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
NZ708526A (en) Novel rock inhibitors
MA39289A (fr) Formulations pharmaceutiques de vilanterol
MA39288A (fr) Formulations pharmaceutiques comprenant du vilanterol
EA201890789A1 (ru) Содержащая цинеол композиция для лечения заболеваний носа
MA54630B1 (fr) N,n-bis-2-mercaptoéthyle isophtalamide pour le traitement des maladies neurodégénératives
MX2021014093A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
Toellner et al. C38 UNDERSTANDING THERAPEUTICS IN IPF: Clinical Experience With Nintedanib For Idiopathic Pulmonary Fibrosis In 3 Uk Tertiary Interstitial Lung Disease Centres
TR201716203A1 (tr) Yeni umeklidinyum formülasyonları.